What’s fishy about protamine? Clinical use, adverse reactions, and potential alternatives
Journal of Thrombosis and Haemostasis · 2023
DOI: 10.1016/j.jtha.2023.04.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Jerrold H Levy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Anesthesiology, Critical Care, and Surgery (Cardiothoracic), Duke University School of Medicine, Durham, North Carolina, USA. Electron…. Hauptthemen laut MEDLINE: Protamines, Heparin. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: Octapharma, Japan Blood Products Organization, University of British Columbia.
Abstract (Originalsprache)
Protamine, a highly basic protein isolated from salmon sperm, is the only clinically available agent to reverse the anticoagulation of unfractionated heparin. Following intravenous administration, protamine binds to heparin in a nonspecific electrostatic interaction to reverse its anticoagulant effects. In clinical use, protamine is routinely administered to reverse high-dose heparin anticoagulation in cardiovascular procedures, including cardiac surgery with cardiopulmonary bypass. Despite the lack of supportive evidence regarding protamine's effectiveness to reverse low-molecular-weight heparin, it is recommended in guidelines with low-quality evidence. Different dosing strategies have been reported for reversing heparin in cardiac surgical patients based on empiric dosing, pharmacokinetics, or point-of-care measurements of heparin levels. Protamine administration is associated with a spectrum of adverse reactions that range from vasodilation to life-threatening cardiopulmonary dysfunction and shock. The life-threatening responses appear to be hypersensitivity reactions due to immunoglobulin E and/or immunoglobulin G antibodies. However, protamine and heparin-protamine complexes can activate complement inflammatory pathways and inhibit other coagulation factors. Although alternative agents for reversing heparin are not currently available for clinical use, additional research continues evaluating novel therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Anesthesiology, Critical Care, and Surgery (Cardiothoracic), Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: jerrold.levy@duke.edu.
- Departments of Anesthesiology and Critical Care, Duke University School of Medicine, Durham, North Carolina, USA.
- Centre for Blood Research, Department of Pathology and Laboratory Medicine, The School of Biomedical Engineering, The University of British Columbia, Vancouver, British Colombia, Canada.
- Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Förderung
- Octapharma
- Japan Blood Products Organization
- University of British Columbia
Zitieren
APA
Levy, J. H., Ghadimi, K., Kizhakkedathu, J. N., & Iba, T. (2023). What’s fishy about protamine? Clinical use, adverse reactions, and potential alternatives. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.04.005
Vancouver
Levy JH, Ghadimi K, Kizhakkedathu JN, Iba T. What’s fishy about protamine? Clinical use, adverse reactions, and potential alternatives. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.04.005
BibTeX
@article{Levy2023,
author = {Levy, Jerrold H and Ghadimi, Kamrouz and Kizhakkedathu, Jayachandran N and Iba, Toshiaki},
title = {What’s fishy about protamine? Clinical use, adverse reactions, and potential alternatives},
journal = {Journal of Thrombosis and Haemostasis},
year = {2023},
doi = {10.1016/j.jtha.2023.04.005}
}
EUVIMED